<p>Fmr LLC 在最近向證券交易委員會提交的文件中表示，在第四季度減少了對 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - 免費報告) 的持股比例，降幅為 0.4%。該基金在此期間出售了 45,207 股後，持有該生物製藥公司 11,076,445 股股票。Fmr LLC 在最近的報告期末持有 Intra-Cellular Therapies 10.42% 的股份，價值 925,105,000 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 01/13 - 01/17</li>
</ul>
<p>其他一些對沖基金也最近調整了對 ITCI 的持股。先鋒集團（Vanguard Group Inc.）在第四季度將其在 Intra-Cellular Therapies 的持股提高了 1.0%。先鋒集團目前持有該生物製藥公司 9,721,360 股股票，價值 811,928,000 美元，此前在上個季度又購買了 93,107 股。挪威銀行（Norges Bank）在第四季度新購入了 Intra-Cellular Therapies 的股份，價值約 268,347,000 美元。州街公司（State Street Corp）在第三季度將其在 Intra-Cellular Therapies 的股份提高了 3.1%。州街公司目前持有該生物製藥公司 1,858,915 股股票，價值 136,017,000 美元，此前在上個季度又購買了 56,664 股。富蘭克林資源公司（Franklin Resources Inc.）在第四季度將其在 Intra-Cellular Therapies 的持股提高了 1.3%。富蘭克林資源公司目前持有該生物製藥公司 1,776,880 股股票，價值 148,405,000 美元，此前在此期間又購買了 23,594 股。最後，Geode Capital Management LLC 在第四季度將其在 Intra-Cellular Therapies 的持股提高了 0.5%。Geode Capital Management LLC 目前持有該生物製藥公司 1,716,829 股股票，價值 143,434,000 美元，此前在上個季度又收購了 8,528 股。對沖基金和其他機構投資者持有該公司 92.33% 的股份。</p>
<h2>Intra-Cellular Therapies 股票表現</h2>
<p>ITCI 股票週二開盤價為 131.87 美元。Intra-Cellular Therapies, Inc. 的 12 個月最低價為 64.09 美元，最高價為 131.98 美元。該股票的市值為 140.5 億美元，市盈率為-151.57，貝塔值為 0.69。該股票的 50 日移動平均線為 129.71 美元，200 日移動平均線為 102.19 美元。</p>
<ul>
<li>強生股票是否準備回報長期持有者？</li>
</ul>
<p>Intra-Cellular Therapies (NASDAQ:ITCI - 獲取免費報告) 最近一次發佈財報是在 2 月 21 日，生物製藥公司報告該季度每股收益（EPS）為-0.16，低於市場共識預期的-0.08，差距為-0.08。Intra-Cellular Therapies 的股本回報率為-9.93%，淨利潤率為-14.07%。該公司該季度的收入為 1.9922 億美元，而分析師預期為 2.0508 億美元。研究分析師平均預測 Intra-Cellular Therapies, Inc. 在當前財年將發佈-0.64 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>一些股票研究分析師對 ITCI 股票發表了看法。Cantor Fitzgerald 在 4 月 2 日的報告中重申了 “中性” 評級，並對 Intra-Cellular Therapies 的股票設定了 132.00 美元的目標價。加拿大皇家銀行（Royal Bank of Canada）在 1 月 22 日的研究報告中重申了 “行業表現” 評級，並將 Intra-Cellular Therapies 的目標價上調至 132.00 美元（之前為 108.00 美元）。Needham &amp; Company LLC 在 2 月 21 日的研究報告中重申了對 Intra-Cellular Therapies 的 “持有” 評級。StockNews.com 在週六對 Intra-Cellular Therapies 開始覆蓋，並對該股票給予 “持有” 評級。最後，Baird R W 在 1 月 13 日的報告中將 Intra-Cellular Therapies 的評級從 “強力買入” 下調至 “持有”。共有 11 位研究分析師對該股票給予 “持有” 評級，5 位分析師給予該公司 “買入” 評級。根據 MarketBeat 的數據，該股票的平均評級為 “持有”，共識目標價為 106.23 美元。</p>
<ul>
<li>百時美施貴寶的大手筆收購：18.1 億美元的兩筆生物科技交易</li>
</ul>
<p><strong>獲取我們關於 Intra-Cellular Therapies 的最新股票報告</strong></p>
<h2>Intra-Cellular Therapies 公司簡介</h2>
<p>（免費報告）</p>
<p>Intra-Cellular Therapies, Inc. 是一家生物製藥公司，專注於小分子藥物的發現、臨牀開發和商業化，這些藥物主要針對神經精神和神經系統疾病的醫療需求，通過靶向中樞神經系統（CNS）中的細胞內信號機制。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Intra-Cellular Therapies</li>
<li>股票中的缺口上漲意味着什麼？如何操作缺口</li>
<li>期權活動指向 Palantir 股票的更多波動性</li>
<li>選舉股票：選舉如何影響股市</li>
<li>NVIDIA 股票：被低估，超賣——能跌到多低？</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>MicroStrategy 在第一季度看到內部買賣活動</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Intra-Cellular Therapies 嗎？</h2>
<p>在考慮 Intra-Cellular Therapies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Intra-Cellular Therapies 並不在名單上。</p>
<p>雖然 Intra-Cellular Therapies 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ITCI

<p>Fmr LLC 在第四季度將其在 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) 的持股減少了 0.4%，目前持有 11,076,445 股，價值 9.251 億美元。其他對沖基金，包括先鋒集團和挪威銀行，也調整了他們的持倉。ITCI 股票開盤價為 131.87 美元，12 個月的價格區間為 64.09 美元至 131.98 美元。該公司報告每股虧損 0.16 美元，未達到預期，收入為 1.9922 億美元。分析師維持 “持有” 評級，普遍目標價為 106.23 美元</p>

<p>Fmr LLC lessened its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 11,076,445 shares of the biopharmaceutical company's stock after selling 45,207 shares during the period. Fmr LLC owned 10.42% of Intra-Cellular Therapies worth $925,105,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Fmr LLC 在最近向證券交易委員會提交的文件中表示，在第四季度減少了對 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - 免費報告) 的持股比例，降幅為 0.4%。該基金在此期間出售了 45,207 股後，持有該生物製藥公司 11,076,445 股股票。Fmr LLC 在最近的報告期末持有 Intra-Cellular Therapies 10.42% 的股份，價值 925,105,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 01/13 - 01/17</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 01/13 - 01/17</li>
</ul>
</div><p>A number of other hedge funds have also recently modified their holdings of ITCI. Vanguard Group Inc. raised its holdings in Intra-Cellular Therapies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company's stock worth $811,928,000 after purchasing an additional 93,107 shares in the last quarter. Norges Bank bought a new position in Intra-Cellular Therapies in the fourth quarter worth about $268,347,000. State Street Corp raised its stake in Intra-Cellular Therapies by 3.1% in the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after buying an additional 56,664 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Intra-Cellular Therapies by 1.3% in the fourth quarter. Franklin Resources Inc. now owns 1,776,880 shares of the biopharmaceutical company's stock worth $148,405,000 after buying an additional 23,594 shares during the period. Finally, Geode Capital Management LLC boosted its position in Intra-Cellular Therapies by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,716,829 shares of the biopharmaceutical company's stock valued at $143,434,000 after acquiring an additional 8,528 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金也最近調整了對 ITCI 的持股。先鋒集團（Vanguard Group Inc.）在第四季度將其在 Intra-Cellular Therapies 的持股提高了 1.0%。先鋒集團目前持有該生物製藥公司 9,721,360 股股票，價值 811,928,000 美元，此前在上個季度又購買了 93,107 股。挪威銀行（Norges Bank）在第四季度新購入了 Intra-Cellular Therapies 的股份，價值約 268,347,000 美元。州街公司（State Street Corp）在第三季度將其在 Intra-Cellular Therapies 的股份提高了 3.1%。州街公司目前持有該生物製藥公司 1,858,915 股股票，價值 136,017,000 美元，此前在上個季度又購買了 56,664 股。富蘭克林資源公司（Franklin Resources Inc.）在第四季度將其在 Intra-Cellular Therapies 的持股提高了 1.3%。富蘭克林資源公司目前持有該生物製藥公司 1,776,880 股股票，價值 148,405,000 美元，此前在此期間又購買了 23,594 股。最後，Geode Capital Management LLC 在第四季度將其在 Intra-Cellular Therapies 的持股提高了 0.5%。Geode Capital Management LLC 目前持有該生物製藥公司 1,716,829 股股票，價值 143,434,000 美元，此前在上個季度又收購了 8,528 股。對沖基金和其他機構投資者持有該公司 92.33% 的股份。</p>
</div><h2>Intra-Cellular Therapies Stock Performance</h2>
<div class="lb-trans"><h2>Intra-Cellular Therapies 股票表現</h2>
</div><p>Shares of ITCI stock opened at $131.87 on Tuesday. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98. The stock has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The stock has a 50 day moving average of $129.71 and a 200 day moving average of $102.19.</p>
<div class="lb-trans"><p>ITCI 股票週二開盤價為 131.87 美元。Intra-Cellular Therapies, Inc. 的 12 個月最低價為 64.09 美元，最高價為 131.98 美元。該股票的市值為 140.5 億美元，市盈率為-151.57，貝塔值為 0.69。該股票的 50 日移動平均線為 129.71 美元，200 日移動平均線為 102.19 美元。</p>
</div><ul>
<li>Is Johnson &amp; Johnson Stock Set to Reward Long-Term Holders?</li>
</ul>
<div class="lb-trans"><ul>
<li>強生股票是否準備回報長期持有者？</li>
</ul>
</div><p>Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. On average, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Intra-Cellular Therapies (NASDAQ:ITCI - 獲取免費報告) 最近一次發佈財報是在 2 月 21 日，生物製藥公司報告該季度每股收益（EPS）為-0.16，低於市場共識預期的-0.08，差距為-0.08。Intra-Cellular Therapies 的股本回報率為-9.93%，淨利潤率為-14.07%。該公司該季度的收入為 1.9922 億美元，而分析師預期為 2.0508 億美元。研究分析師平均預測 Intra-Cellular Therapies, Inc. 在當前財年將發佈-0.64 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of equities research analysts have weighed in on ITCI shares. Cantor Fitzgerald restated a &#34;neutral&#34; rating and issued a $132.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Royal Bank of Canada restated a &#34;sector perform&#34; rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Saturday. They issued a &#34;hold&#34; rating on the stock. Finally, Baird R W downgraded Intra-Cellular Therapies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of &#34;Hold&#34; and a consensus price target of $106.23.</p>
<div class="lb-trans"><p>一些股票研究分析師對 ITCI 股票發表了看法。Cantor Fitzgerald 在 4 月 2 日的報告中重申了 “中性” 評級，並對 Intra-Cellular Therapies 的股票設定了 132.00 美元的目標價。加拿大皇家銀行（Royal Bank of Canada）在 1 月 22 日的研究報告中重申了 “行業表現” 評級，並將 Intra-Cellular Therapies 的目標價上調至 132.00 美元（之前為 108.00 美元）。Needham &amp; Company LLC 在 2 月 21 日的研究報告中重申了對 Intra-Cellular Therapies 的 “持有” 評級。StockNews.com 在週六對 Intra-Cellular Therapies 開始覆蓋，並對該股票給予 “持有” 評級。最後，Baird R W 在 1 月 13 日的報告中將 Intra-Cellular Therapies 的評級從 “強力買入” 下調至 “持有”。共有 11 位研究分析師對該股票給予 “持有” 評級，5 位分析師給予該公司 “買入” 評級。根據 MarketBeat 的數據，該股票的平均評級為 “持有”，共識目標價為 106.23 美元。</p>
</div><ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>百時美施貴寶的大手筆收購：18.1 億美元的兩筆生物科技交易</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on Intra-Cellular Therapies</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Intra-Cellular Therapies 的最新股票報告</strong></p>
</div><h2>Intra-Cellular Therapies Company Profile</h2>
<div class="lb-trans"><h2>Intra-Cellular Therapies 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.</p>
<div class="lb-trans"><p>Intra-Cellular Therapies, Inc. 是一家生物製藥公司，專注於小分子藥物的發現、臨牀開發和商業化，這些藥物主要針對神經精神和神經系統疾病的醫療需求，通過靶向中樞神經系統（CNS）中的細胞內信號機制。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Intra-Cellular Therapies</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>Options Activity Points to More Volatility for Palantir Stock</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>MicroStrategy Sees Insider Buy-Sell Action in Q1</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Intra-Cellular Therapies</li>
<li>股票中的缺口上漲意味着什麼？如何操作缺口</li>
<li>期權活動指向 Palantir 股票的更多波動性</li>
<li>選舉股票：選舉如何影響股市</li>
<li>NVIDIA 股票：被低估，超賣——能跌到多低？</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>MicroStrategy 在第一季度看到內部買賣活動</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ITCI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intra-Cellular Therapies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Intra-Cellular Therapies 嗎？</h2>
</div><p>Before you consider Intra-Cellular Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Intra-Cellular Therapies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Intra-Cellular Therapies 並不在名單上。</p>
</div><p>While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Intra-Cellular Therapies 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Fmr LLC 減少了在 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) 的持股